Manish K Jha1, Bruce D Grannemann1, Joseph M Trombello1, E Will Clark1, Sara Levinson Eidelman1, Tiffany Lawson1, Tracy L Greer1, A John Rush1, Madhukar H Trivedi2. 1. Center for Depression Research and Clinical Care, UT Southwestern Medical Center, Dallas, Texas (Jha, Granneman, Trombello, Clark, Eidelman, Greer, Trivedi); Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York (Jha); Duke-National University of Singapore, Singapore (Rush); Department of Psychiatry, Duke Medical School, Durham, North Carolina (Rush); Texas Tech University-Health Sciences Center, Permian Basin, Texas (Rush). 2. Center for Depression Research and Clinical Care, UT Southwestern Medical Center, Dallas, Texas (Jha, Granneman, Trombello, Clark, Eidelman, Greer, Trivedi); Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York (Jha); Duke-National University of Singapore, Singapore (Rush); Department of Psychiatry, Duke Medical School, Durham, North Carolina (Rush); Texas Tech University-Health Sciences Center, Permian Basin, Texas (Rush) madhukar.trivedi@utsouthwestern.edu.
Abstract
PURPOSE: This report describes outcomes of an ongoing quality-improvement project (VitalSign6) in a large US metropolitan area to improve recognition, treatment, and outcomes of depressed patients in 16 primary care clinics (6 charity clinics, 6 federally qualified health care centers, 2 private clinics serving low-income populations, and 2 private clinics serving patients with either Medicare or private insurance). METHODS: Inclusion in this retrospective analysis was restricted to the first 25,000 patients (aged ≥12 years) screened with the 2-item Patient Health Questionnaire (PHQ-2) in the aforementioned quality-improvement project. Further evaluations with self-reports and clinician assessments were recorded for those with positive screen (PHQ-2 >2). Data collected from August 2014 though November 2016 were available at 3 levels: (1) initial PHQ-2 (n = 25,000), (2) positive screen (n = 4,325), and (3) clinician-diagnosed depressive disorder with 18 or more weeks of enrollment (n = 2,160). RESULTS: Overall, 17.3% (4,325/25,000) of patients screened positive for depression. Of positive screens, 56.1% (2,426/4,325) had clinician-diagnosed depressive disorder. Of those enrolled for 18 or more weeks, 64.8% were started on measurement-based pharmacotherapy and 8.9% referred externally. Of the 1,400 patients started on pharmacotherapy, 45.5%, 30.2%, 12.6%, and 11.6% had 0, 1, 2, and 3 or more follow-up visits, respectively. Remission rates were 20.3% (86/423), 31.6% (56/177), and 41.7% (68/163) for those with 1, 2, and 3 or more follow-up visits, respectively. Baseline characteristics associated with higher attrition were: non-white, positive drug-abuse screen, lower depression/anxiety symptom severity, and younger age. CONCLUSION: Although remission rates are high in those with 3 or more follow-up visits after routine screening and treatment of depression, attrition from care is a significant issue adversely affecting outcomes.
PURPOSE: This report describes outcomes of an ongoing quality-improvement project (VitalSign6) in a large US metropolitan area to improve recognition, treatment, and outcomes of depressedpatients in 16 primary care clinics (6 charity clinics, 6 federally qualified health care centers, 2 private clinics serving low-income populations, and 2 private clinics serving patients with either Medicare or private insurance). METHODS: Inclusion in this retrospective analysis was restricted to the first 25,000 patients (aged ≥12 years) screened with the 2-item Patient Health Questionnaire (PHQ-2) in the aforementioned quality-improvement project. Further evaluations with self-reports and clinician assessments were recorded for those with positive screen (PHQ-2 >2). Data collected from August 2014 though November 2016 were available at 3 levels: (1) initial PHQ-2 (n = 25,000), (2) positive screen (n = 4,325), and (3) clinician-diagnosed depressive disorder with 18 or more weeks of enrollment (n = 2,160). RESULTS: Overall, 17.3% (4,325/25,000) of patients screened positive for depression. Of positive screens, 56.1% (2,426/4,325) had clinician-diagnosed depressive disorder. Of those enrolled for 18 or more weeks, 64.8% were started on measurement-based pharmacotherapy and 8.9% referred externally. Of the 1,400 patients started on pharmacotherapy, 45.5%, 30.2%, 12.6%, and 11.6% had 0, 1, 2, and 3 or more follow-up visits, respectively. Remission rates were 20.3% (86/423), 31.6% (56/177), and 41.7% (68/163) for those with 1, 2, and 3 or more follow-up visits, respectively. Baseline characteristics associated with higher attrition were: non-white, positive drug-abuse screen, lower depression/anxiety symptom severity, and younger age. CONCLUSION: Although remission rates are high in those with 3 or more follow-up visits after routine screening and treatment of depression, attrition from care is a significant issue adversely affecting outcomes.
Keywords:
antidepressants; depression; health care delivery/HSR; loss to follow-up; major depressive disorder; measurement-based care; primary care issues; primary health care; quality improvement; quality of care
Authors: Diane Warden; Madhukar H Trivedi; Stephen R Wisniewski; Lori Davis; Andrew A Nierenberg; Bradley N Gaynes; Sidney Zisook; Steven D Hollon; G K Balasubramani; Robert Howland; Maurizio Fava; Jonathan W Stewart; A John Rush Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112
Authors: R H Perlis; D V Iosifescu; V M Castro; S N Murphy; V S Gainer; J Minnier; T Cai; S Goryachev; Q Zeng; P J Gallagher; M Fava; J B Weilburg; S E Churchill; I S Kohane; J W Smoller Journal: Psychol Med Date: 2011-06-20 Impact factor: 7.723
Authors: Michelle A Blackmore; Kelly E Carleton; Sarah M Ricketts; Urvashi B Patel; Dana Stein; Alissa Mallow; Joseph P Deluca; Henry Chung Journal: Psychiatr Serv Date: 2018-08-28 Impact factor: 3.084
Authors: Pawel Posadzki; Nikolaos Mastellos; Rebecca Ryan; Laura H Gunn; Lambert M Felix; Yannis Pappas; Marie-Pierre Gagnon; Steven A Julious; Liming Xiang; Brian Oldenburg; Josip Car Journal: Cochrane Database Syst Rev Date: 2016-12-14
Authors: Elizabeth R Pfoh; Isabel Janmey; Amit Anand; Kathryn A Martinez; Irene Katzan; Michael B Rothberg Journal: J Gen Intern Med Date: 2020-06-03 Impact factor: 5.128
Authors: Olivia E Bogucki; Mark D Williams; Leif I Solberg; Rebecca C Rossom; Craig N Sawchuk Journal: Curr Psychiatry Rep Date: 2020-07-14 Impact factor: 5.285
Authors: Kimberly A Siniscalchi; Marion E Broome; Jason Fish; Joseph Ventimiglia; Julie Thompson; Pratibha Roy; Ronny Pipes; Madhukar Trivedi Journal: J Prim Care Community Health Date: 2020 Jan-Dec
Authors: Kristin Martin-Cook; Lucy Palmer; Larry Thornton; A John Rush; Carol A Tamminga; Hicham M Ibrahim Journal: Neuropsychiatr Dis Treat Date: 2021-05-25 Impact factor: 2.570